Other news Stine Krag Brunvold 10/24/22 Other news Stine Krag Brunvold 10/24/22 NMD Pharma is attending BIO Europe Read More Events Stine Krag Brunvold 10/11/22 Events Stine Krag Brunvold 10/11/22 Today we are able to announce positive topline data from our Phase I/IIa clinical trial of NMD670 in patients with Myasthenia Gravis Read More Press release Stine Krag Brunvold 10/11/22 Press release Stine Krag Brunvold 10/11/22 NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Read More Other news Stine Krag Brunvold 9/30/22 Other news Stine Krag Brunvold 9/30/22 Thomas Holm Pedersen speaks at The First Nordic Conference on Myasthenia Gravis Read More Press release Stine Krag Brunvold 9/27/22 Press release Stine Krag Brunvold 9/27/22 FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis Read More Other news Stine Krag Brunvold 9/16/22 Other news Stine Krag Brunvold 9/16/22 Thomas Holm Pedersen speaks at The Global CMT Research Convention Read More Other news Stine Krag Brunvold 9/7/22 Other news Stine Krag Brunvold 9/7/22 The INCUBA Awards Read More Other news Stine Krag Brunvold 9/6/22 Other news Stine Krag Brunvold 9/6/22 NMD Pharma will be at LSX Nordic Congress Read More Other news Stine Krag Brunvold 9/1/22 Other news Stine Krag Brunvold 9/1/22 CMT Awareness Month in the US Read More Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22 NMD Pharma at ICFSR 2022 - Symposium 4 - Part 1 Read More Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22 NMD Pharma at ICFSR 2022 - Symposium 4 - Part 2 Read More Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22 NMD Pharma at ICFSR 2022 - Symposium 4 - Part 3 Read More Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22 NMD Pharma at ICFSR 2022 - Symposium 4 - Part 4 - Q&A Read More Insights Stine Krag Brunvold 8/8/22 Insights Stine Krag Brunvold 8/8/22 Spinal Muscular Atrophy (SMA) Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Eden Read More Other news Stine Krag Brunvold 8/2/22 Other news Stine Krag Brunvold 8/2/22 What happens day-to-day in the life of a Research Scientist at NMD Pharma? Read More Events Stine Krag Brunvold 7/7/22 Events Stine Krag Brunvold 7/7/22 An active future made possible by the power of science Read More Other news Stine Krag Brunvold 7/5/22 Other news Stine Krag Brunvold 7/5/22 Our team will be attending the 17th ICNMD 2022 in Brussels Read More Insights Stine Krag Brunvold 6/21/22 Insights Stine Krag Brunvold 6/21/22 Myasthenia Gravis Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Ulrik Read More Other news Stine Krag Brunvold 6/16/22 Other news Stine Krag Brunvold 6/16/22 We will be participating in the Cure SMA 2022 conference Read More Insights Stine Krag Brunvold 6/16/22 Insights Stine Krag Brunvold 6/16/22 Myasthenia Gravis Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Sofie Read More Newer Posts Older Posts
Other news Stine Krag Brunvold 10/24/22 Other news Stine Krag Brunvold 10/24/22 NMD Pharma is attending BIO Europe Read More
Events Stine Krag Brunvold 10/11/22 Events Stine Krag Brunvold 10/11/22 Today we are able to announce positive topline data from our Phase I/IIa clinical trial of NMD670 in patients with Myasthenia Gravis Read More
Press release Stine Krag Brunvold 10/11/22 Press release Stine Krag Brunvold 10/11/22 NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Read More
Other news Stine Krag Brunvold 9/30/22 Other news Stine Krag Brunvold 9/30/22 Thomas Holm Pedersen speaks at The First Nordic Conference on Myasthenia Gravis Read More
Press release Stine Krag Brunvold 9/27/22 Press release Stine Krag Brunvold 9/27/22 FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis Read More
Other news Stine Krag Brunvold 9/16/22 Other news Stine Krag Brunvold 9/16/22 Thomas Holm Pedersen speaks at The Global CMT Research Convention Read More
Other news Stine Krag Brunvold 9/7/22 Other news Stine Krag Brunvold 9/7/22 The INCUBA Awards Read More
Other news Stine Krag Brunvold 9/6/22 Other news Stine Krag Brunvold 9/6/22 NMD Pharma will be at LSX Nordic Congress Read More
Other news Stine Krag Brunvold 9/1/22 Other news Stine Krag Brunvold 9/1/22 CMT Awareness Month in the US Read More
Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22 NMD Pharma at ICFSR 2022 - Symposium 4 - Part 1 Read More
Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22 NMD Pharma at ICFSR 2022 - Symposium 4 - Part 2 Read More
Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22 NMD Pharma at ICFSR 2022 - Symposium 4 - Part 3 Read More
Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22 NMD Pharma at ICFSR 2022 - Symposium 4 - Part 4 - Q&A Read More
Insights Stine Krag Brunvold 8/8/22 Insights Stine Krag Brunvold 8/8/22 Spinal Muscular Atrophy (SMA) Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Eden Read More
Other news Stine Krag Brunvold 8/2/22 Other news Stine Krag Brunvold 8/2/22 What happens day-to-day in the life of a Research Scientist at NMD Pharma? Read More
Events Stine Krag Brunvold 7/7/22 Events Stine Krag Brunvold 7/7/22 An active future made possible by the power of science Read More
Other news Stine Krag Brunvold 7/5/22 Other news Stine Krag Brunvold 7/5/22 Our team will be attending the 17th ICNMD 2022 in Brussels Read More
Insights Stine Krag Brunvold 6/21/22 Insights Stine Krag Brunvold 6/21/22 Myasthenia Gravis Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Ulrik Read More
Other news Stine Krag Brunvold 6/16/22 Other news Stine Krag Brunvold 6/16/22 We will be participating in the Cure SMA 2022 conference Read More
Insights Stine Krag Brunvold 6/16/22 Insights Stine Krag Brunvold 6/16/22 Myasthenia Gravis Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Sofie Read More
